Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Multicenter, Open-Label, Randomized, Comparator Controlled Trial of the Safety and Efficacy of Dalbavancin Versus Active Comparator in Pediatric Subjects With Acute Bacterial Skin and Skin Structure Infections

NCT02814916 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT02814916
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02814916 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Multicenter, Open-Label, Randomized, Comparator Controlled Trial of the Safety and Efficacy of Dalbavancin Versus Active Comparator in Pediatric Subjects With Acute Bacterial Skin and Skin Structure Infections
Lead sponsor
AbbVie
Phase
Phase 3
Overall status
Completed
Start date
March 30, 2017
Completion date
January 1, 2024
Enrollment
199 (actual)
Sites
84

Conditions

As the registry lists them; a condition with its own page is linked.

bacterial infections, methicillin-resistant staphylococcus aureus, staphylococcal skin infections